Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2019 Dec 1;82(4):392–398. doi: 10.1097/QAI.0000000000002149

Table 5.

Simulated dose regimen scenarios with exposure assessments. Exposure targets are Ctrough > 0.033 mg/L, Cmax < 8.72mg/L, AUC0–24 < 40 mg*hr/L and AUC0–12 < 20mg*hr/L. Green cells show that exposure target has been met, red cells denote violation of the exposure target at indicated day(s) and yellow cells denote that exposure is close to the target at the indicated day(s). Raltegravir doses indicated expressed in mg/kg.

Regimen Day 1–7 (wk-1) Day 8–14 (wk-2) Day 15–21 (wk-3) Day 22–28 (wk-4) Day 29–35 (wk-5) Day 36–42 (wk-6) Ctrough Cmax AUC0–24 (QD) AUC0–12 (BID)
1 2 QD 3 BID Day42 Days 2+3
2 3 QD 3 BID 4 BID Day42 Days 2+3
3 2 QD 2 BID 6 BID Day28 Days 2+3
4 2 QD 2 BID 6 BID Days 2+3 Days 14–16
5 3 QD 3 BID 6 BID Day 14 Days 2+3
6 2 QD 4 QD 6 BID Days 2+3 Days 14–16
7 2 QD 3 BID 6 BID Days 2+3
8 2 QD 6 QD 6 BID Day 28 Days 2+3
9 3 QD 3 BID 6 BID Days 2+3
10 1.5 QD 3 BID 6 BID

wk: week; QD: once daily; BID: twice daily; AUC0–24 assessed for days with QD dosing only; AUC0–12 assessed for days with BID dosing only